Abstract
The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Current Topics in Medicinal Chemistry
Title: The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors
Volume: 2 Issue: 9
Author(s): Pier F. Cirillo, Christopher Pargellis and John Regan
Affiliation:
Keywords: kinase inhibition, anti-cancer agents, purine-derived compounds, cell cycle, solid phase synthesis, biological activity
Abstract: The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.
Export Options
About this article
Cite this article as:
Cirillo F. Pier, Pargellis Christopher and Regan John, The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors, Current Topics in Medicinal Chemistry 2002; 2 (9) . https://dx.doi.org/10.2174/1568026023393390
DOI https://dx.doi.org/10.2174/1568026023393390 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Practical Considerations in the Development of Hemoglobin-Based Oxygen Therapeutics
Current Drug Discovery Technologies Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Pharmacological Inhibitors of Cysteinyl Leukotrienes Biosynthesis: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options
Current Respiratory Medicine Reviews BRCA Unclassified Variants: How Can They be Classified?
Current Women`s Health Reviews Structural and Molecular Basis of Carbohydrate-Protein Interaction Systems as Potential Therapeutic Targets
Current Pharmaceutical Design Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options
Current Pharmaceutical Design An Angiotensin Converting Enzyme Inhibitor Suppresses Contrast Media Induced Renal Dysfunction in a Murine Model of Subtotal Nephrectomy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic: Essential Fatty Acids (Guest Editor: Undurti N. Das)]
Current Pharmaceutical Biotechnology Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Current Diabetes Reviews Novel Strategies for the Treatment of Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) Subject Index To Volume 3
Current Neurovascular Research Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews